drugset / Trial / NCT07269782
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Timeline
- Start
- 2026-01-20
- Primary completion
- 2026-07-10
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | — | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | — | Intravenous |